Vertex faces pressure from potential U.S. drug pricing reforms and tariffs. Click here to find out why VRTX stock is a Hold.

Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. Click here to read more.

Acumatica has announced the general availability of its 2025 R2 ERP Platform. The R2 release features new and updated enhancements that improve usability, ...

Vertex has begun a full-court press for Journavx, enlisting NBA All-Star Jayson Tatum to discuss his use of the new ...

Ratings for Vertex Pharmaceuticals (NASDAQ: VRTX) were provided by 15 analysts in the past three months, showcasing a mix of ...

Vertex Minerals (ASX:VTX) is still in the early stages of developing its underground mine, and while the production ramp-up was slowed by delays in high-voltage equipment delivery and commissioning, ...

The FDA granted breakthrough therapy designation to a Vertex Pharmaceuticals kidney disease drug.

Vertex Pharmaceuticals (VRTX) announced that the FDA has granted breakthrough therapy designation to povetacicept for the treatment of IgAN. Pove ...

As previously reported, Leerink upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Market Perform with a price target of $456, down from ...

Some leaders use humor instinctively; many more could wield it purposefully. by Brad Bitterly and Alison Wood Brooks A few years ago, we conducted a research study in which we asked people to help us ...